Cas:1057089-70-9 N-pyridin-2-yl-5-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide manufacturer & supplier

Chemical Name:N-pyridin-2-yl-5-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide

CAS.NO:1057089-70-9

Synonyms:N-pyridin-2-yl-5-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide

Molecular Formula:C₁₈H₁₂F₃N₃O

Molecular Weight:343.30300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:58.37000

Exact Mass:343.09300

LogP:4.79870

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-pyridin-2-yl-5-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-pyridin-2-yl-5-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-pyridin-2-yl-5-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Use and application,N-pyridin-2-yl-5-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide technical grade,usp/ep/jp grade.

Related News: The European Commission (EC) has approved MSD and Bayer’s Verquvo for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction. 5,8-Difluoroquinoline manufacturers As for the consumer health unit, GSK plans to demerge it by mid-2022, during which GSK will shed at least 80% of its 68% holding in the JV to shareholders. 4-Propionylbiphenyl suppliers In 2018, the Bengaluru-based Natural Capsules set up an R&D centre in at Attibele, Bengaluru. In 2020, when PLI scheme was announced it applied for the same. imino(diphenyl)-λ4-sulfane,hydrate vendor & factory CHMP also recommended for approval Sanofi and Genzyme’s new Pompe disease drug, known in Europe as Nexviadyme (avalglucosidase alfa). Pompe disease is a rare, inherited disorder caused by the buildup of glycogen in the body’s cells.,CHMP also recommended for approval Sanofi and Genzyme’s new Pompe disease drug, known in Europe as Nexviadyme (avalglucosidase alfa). Pompe disease is a rare, inherited disorder caused by the buildup of glycogen in the body’s cells.